CHARLOTTE – United Therapeutics is building a $500 million manufacturing facility in Research Triangle Park to expand production of a drug-device combination product that received approval by the U.S. Food and Drug Administration last year.

The product, Tyvaso DPI, is part of the multibillion-dollar company’s growth strategy as it aims to double its revenue in the coming years.

More United Therapeutics News

United Therapeutics opens a net zero energy center in RTP